COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

Key Inclusion Criteria: * Histologically or cytologically confirmed, locally advanced or metastatic solid malignancy and has exhausted all available standard therapy or is not a candidate for the available standard therapy. * Eastern Cooperative Oncology Group (ECOG) performance status 0-1. * During dose escalation - Subjects who received prior therapy with anti-PD-1, anti-PD-L1, anti- CTLA-4, OX-40, CD137, etc., are eligible. During cohort expansion: All subjects must have measurable disease as defined by RECIST v1.1. Expansion Cohorts: * Cohort 1 (subjects with advanced epithelial ovarian, fallopian tube, or primary peritoneal carcinoma) * Subject must have platinum refractory/resistant ovarian cancer defined as refractoriness to platinum-containing regimen or disease recurrence \< 6 months after completion of a platinum-containing regimen * Cohort 2 (endometrial cancer cohort) * Subjects with locally advanced or metastatic microsatellite stable endometrial cancer with disease recurrence or progression during or after prior therapy that included platinum-based chemotherapy. * Subjects must have documented MSS status by an approved test e.g. genomic testing, IHC for mismatch repair proficient. * Subjects must have received no more than 2 prior systemic cytotoxic therapies; there are no limits to the number of prior endocrine or antiangiogenic regimens * Cohort 3 (basket cohort, excludes tumor types in cohorts 1 and 2) * Tumor types with high expression of PVRL2 (determined by central testing). * Cohort 4 (Head and Neck cancer) * Histologically confirmed recurrent or metastatic HNSCC (oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, paranasal sinus, nasopharyngeal) * Cohort 4a - IO naïve. Eligible subjects can be systemic therapy naïve (frontline) or platinum failure. * Cohort 4b - IO failure. No limitations on the number of prior lines of systemic therapy. Key Exclusion Criteria: * Active autoimmune disease requiring systemic therapy in the last 2 years prior to the first dose of COM701. * Symptomatic interstitial lung disease or inflammatory pneumonitis. * History of immune-related events that lead to immunotherapy treatment discontinuation. * Untreated or symptomatic central nervous system (CNS) metastases. Key Exclusion Criteria For Dose Expansion Cohorts: * Cohort 1: Prior therapy with an anti-PD-1/PD-L1/2, COM701 (or any inhibitor of PVRIG), anti-TIGIT antibody, anti-CTLA-4 antibody, anti-OX-40 antibody, anti-CD137 antibody. * Cohort 2: Prior therapy with COM701 (or any inhibitor of PVRIG) or anti-TIGIT antibody. Subjects with MSI-H endometrial cancer are ineligible. * Cohort 3: Prior therapy with COM701 (or any inhibitor of PVRIG) or anti-TIGIT antibody are ineligible. * Cohort 4: Subjects who have received prior therapy with COM701 (or any inhibitor of PVRIG), anti-TIGIT antibody, anti-CTLA-4 antibody, anti-OX-40 antibody, anti-CD137 antibody. Subjects in cohort 4a must be IO-naïve.